Agomab Therapeutics NV raised $40.5 million in a series B extension led by Pfizer Inc., which has also come on board as an adviser on the development of AGMB-129, Agomab’s candidate therapy for fibrostenotic Crohn’s disease. The new cash raises the series B total to $114 million.
Ganymed Robotics SAS raised a €21 million (US$21.2 million) series B round to develop its robotic system for total knee arthroplasty (TKA). Health care fund Cathay Health led the round, with participation from Credit Mutuel Innovation, Kurma Partners, BNP Paribas Developpement, and individual surgeons. The funds will be used to finalize development of Ganymed’s TKA surgical assistant and support the company’s expansion in France and the U.S.
Mirobio Ltd. is poised to take two checkpoint agonists into the clinic in the treatment of autoimmune diseases, after closing a $97 million series B round. The most advanced program, MB-272, is an agonist of the B and T lymphocyte attenuator receptor that relays inhibitory signals to suppress the immune response. Mirobio says activating it has a “far reaching” regulatory effect, restoring self-tolerance across several major autoimmune diseases, including lupus.
Investors are backing imaging diagnostics company Magnetic Insight Inc. with $17 million to develop its magnetic particle imaging (MPI) technology. The clinical imaging application consists of two core technologies: hardware and a tracer that, together, produce 3D images of how a patient’s body works. Venture firm Celesta Capital led the series B round with Alumni Ventures Group, Gaingels and existing investors 5AM Ventures and Sand Hill Angels participating.
Philadelphia’s Mineralys Therapeutics Inc. has secured a further $118 million to develop MLS-101, a potential hypertension drug in-licensed from Mitsubishi Tanabe Pharma Corp.
Immunos Therapeutics AG closed a $74 million series B round to progress its first-in-class, multifunctional immuno-oncology drug candidate, IOS-1002, and to expand further its pipeline of biologic drugs based on immuno-stimulatory human leukocyte antigen molecules.
Luca Science Inc. has raised $30.3 million in an oversubscribed series B financing, enabling it to advance a mitochondria replacement therapy toward the clinic. The company is planning a phase Ib trial in myocardial infarction, in which 8 to 12 patients will receive injections of mitochondria immediately after having a heart attack.
Swanbio Therapeutics Inc. closed a $56 million series B round to take its lead gene therapy program, SBT-101, into clinical development later this year. The candidate, comprised of an adeno-associated virus type 9 vector encoding the ABCD1 peroxisomal ATP-binding cassette transporter, is in development for adrenomyeloneuropathy (AMN), an inherited disease that affects the central nervous system.
With a 2020 launch behind it, Moma Therapeutics Inc. has completed a $150 series B financing to continue refining its pipeline of therapies targeting tough-to-drug enzymes in treating solid tumors.
RSS
